Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease
Ping Zhang, Lingyu Zhang, Lin Li, et al.
Journal of Parkinson s Disease (2019) Vol. 9, Iss. 1, pp. 157-171
Closed Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Role of neuroinflammation in neurodegeneration development
Weifeng Zhang, Dan Xiao, Qinwen Mao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 506
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Chao Gao, Jingwen Jiang, Yuyan Tan, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 410
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 247
Progress towards therapies for disease modification in Parkinson's disease
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 7, pp. 559-572
Open Access | Times Cited: 236
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Maddalena Grieco, Alessandra Giorgi, Maria Cristina Gentile, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 170
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 106
GLP-1a: Going beyond Traditional Use
Lucas Fornari Laurindo, Sandra Maria Barbalho, Élen Landgraf Guiguer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 739-739
Open Access | Times Cited: 70
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 69
The heterogeneity of Parkinson’s disease
Ullrich Wüllner, Per Borghammer, Chi‐un Choe, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 827-838
Open Access | Times Cited: 65
Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway
Zhaojun Wang, Xinru Li, Shi-Fan Chai, et al.
Neuropharmacology (2023) Vol. 240, pp. 109716-109716
Closed Access | Times Cited: 42
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 19
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kallirhoe Kalinderi, Vasileios Papaliagkas, Liana Fidani
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3812-3812
Open Access | Times Cited: 18
Energy metabolism in health and diseases
Hui Liu, Shuo Wang, Jianhua Wang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Christian Hölscher
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 4, pp. 333-348
Open Access | Times Cited: 135
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics
Therese S. Salameh, Elizabeth M. Rhea, Konrad Talbot, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114187-114187
Open Access | Times Cited: 104
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Christian Hölscher
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 695-714
Open Access | Times Cited: 94
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Paul Edison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 217-229
Open Access | Times Cited: 63
Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing
CarmenM Labandeira, Arturo Fraga-Bau, David Arias Ron, et al.
Neural Regeneration Research (2021) Vol. 17, Iss. 8, pp. 1652-1652
Open Access | Times Cited: 61
The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Dihe Cheng, Shuo Yang, Xue Zhao, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 665-684
Open Access | Times Cited: 39
Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats
Tae Suk Lee, Eun Ji Park, Minkyu Choi, et al.
Journal of Chromatography B (2023) Vol. 1221, pp. 123688-123688
Closed Access | Times Cited: 22
Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications
Mateusz Kciuk, Weronika Kruczkowska, Julia Gałęziewska, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11955-11955
Open Access | Times Cited: 11
Drug repositioning for Parkinson’s disease: an emphasis on artificial intelligence approaches
Iman Karimi-Sani, Mehrdad Sharifi, Nahid Abolpour, et al.
Ageing Research Reviews (2025) Vol. 104, pp. 102651-102651
Closed Access | Times Cited: 1
Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives
Rumiana Koynova, Janet M. Sasso, Qiongqiong Angela Zhou
ACS Omega (2025) Vol. 10, Iss. 2, pp. 1864-1892
Open Access | Times Cited: 1
The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke
Xiaoyan Yang, Peng Feng, Xiangjian Zhang, et al.
Neuropharmacology (2019) Vol. 158, pp. 107748-107748
Closed Access | Times Cited: 65
Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review
Fauze Camargo Maluf, David Feder, Alzira Alves de Siqueira Carvalho
Parkinson s Disease (2019) Vol. 2019, pp. 1-14
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top